SAFC Announces Launch of New Integrated Chiral Offer
ST. LOUIS, June 11, 2012 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC® (www.safcglobal.com), will consolidate its global chiral chromatography screening and small scale purification operations and locate them at its Pharmorphix® Solid State Research Laboratories in Cambridge, UK, to support its new integrated chiral chemistry offer. The Cambridge facility will now become the worldwide hub for SAFC's chiral service offering which ranges from Chiral Gas Chromatography (GC) and Liquid Chromatography (LC) Separations, to large scale crystallization, Simulated Moving Bed (SMB) Separations and production of enantiomerically pure Active Pharmaceutical Ingredients (APIs). The consolidation of SAFC's chiral services will provide customers with a single, dedicated point of contact from the development stage through scale up. Paul Rodwell, a former Senior Principal Scientist with Pfizer, has been appointed to lead SAFC's chiral chromatography method development team.
Analytical equipment is currently being installed at the Cambridge site, having been transferred from Sigma-Aldrich subsidiary Supelco Analytical in Bellefonte, PA, where the chiral screening service was previously performed. The chiral screening operation will continue to support the analytical chiral column business and will draw upon Supelco's analytical expertise to complement the solid-form characterization and research services already located at the Cambridge site. The new laboratories are expected to be validated and fully operational in July 2012.
"SAFC offers a robust, cohesive range of chiral services that are applicable for a wide range of markets, from early stage drug discovery to route optimization and product development, through gram to multi kilo scale-up," Rodwell commented.
The SAFC chiral offering already includes separation by commercial-scale SMB chromatography, chiral preparative HPLC, separation by crystallization of diastereomeric salts and determination of the absolute stereochemistry by single crystal X-Ray diffraction. SAFC Chiral Services, combined with Supelco and Aldrich products for chiral chromatography and chemical synthesis, give Sigma-Aldrich a wide portfolio of capabilities and services to support Pharmaceutical, Agrochemical, Fine Chemicals and Food and Fragrances companies from early research to final production of high quality enantiomerically pure compounds.
The foregoing release contains forward-looking statements that can be identified by terminology such as "expected," "will provide," "should," "believe" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. There can be no guarantee that the products in SAFC's chiral service offering will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About SAFC®: SAFC is the custom manufacturing and services business unit of Sigma-Aldrich Corporation. It's recognized as a top 10 global fine chemical supplier and trusted manufacturer of specialty chemicals and biologics for the life science and high technology industries. Utilizing global "Centers of Excellence" and dedicated manufacturing facilities, SAFC can often resolve development and manufacturing challenges and accelerate the production of custom materials. Its rich portfolio includes high-purity inorganic materials for high technology applications, cell culture products, biopharmaceutical lot release and safety testing, services for biopharmaceutical manufacturing and biochemical production, and complex, multi-step organic synthesis of APIs and key intermediates. For more information about SAFC, visit www.safcglobal.com.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 35 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.
SAFC and Sigma-Aldrich are registered trademarks of Sigma-Aldrich Co. LLC.
SOURCE Sigma-Aldrich Corporation
More by this Source
Sigma-Aldrich (NASDAQ: SIAL) Reports Q3 2013 Sales Of $664 Million, Organic Sales Growth Of 5% And Adjusted Diluted EPS Of $1.05. Reaffirms Full Year 2013 Organic Sales Outlook. Narrows Adjusted Diluted EPS Outlook To A New Range Of $4.08 To $4.15
Oct 22, 2013, 07:00 ET
SAFC® Manufacturing New High-Quality PharmaGrade Raw Materials at Arklow, Ireland, Plant
Oct 16, 2013, 07:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.